Immune Checkpoint Inhibitors in Cancer Therapy—How Can We Improve Clinical Benefits?

Dear Colleagues,

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer with durable clinical responses observed even in patients with advanced refractory cancers. ICIs function to block inhibitory signals from tumor cells to immune effector cells, allowing activated T-cells to effectively target malignant cells. In this way, ICIs act to re-activate the antitumor endogenous cellular immunity. Unfortunately, despite the great promise in ICIs, resistance to these agents limits the number of patients able to achieve meaningful clinical benefits. As a result, along with the discovery of novel ICIs, the scientific community is placing efforts on the discovery of biomarkers for selecting patients most likely to respond to ICIs-base immunotherapies. The scope of this Special Issue will be to critically address mechanisms of resistance and/or non-responsiveness to ICI-based immunotherapies and how these can be circumvented via the discovery of novel ICIs, predictive biomarkers, and combinatorial therapeutic strategies.

Prof. Dr. Constantin N. Baxevanis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.